Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (NASDAQ: ARTL) announced a R&D showcase focused on its Phase 1b/2a Cancer Appetite Recovery Study (CAReS) for lead drug candidate ART27.13. Hosted by Ladenburg Thalmann on July 28, 2021, at 1 PM EDT, the webinar will feature lead investigator Barry Laird, PhD. Key topics include the etiology of anorexia and treatment challenges. Artelo is dedicated to therapeutics targeting lipid signaling pathways, addressing critical needs in diseases like anorexia and cancer. More details can be found on their website.
Artelo Biosciences (ARTL) reported progress in its CAReS study for cancer anorexia, anticipating data by year-end. The company has over $10 million in cash as of May 31, 2021, enabling it to advance key milestones. Despite a net loss of $2.25 million for Q3 2021, up from $951,191 in Q3 2020, Artelo is focused on potential therapies that address significant unmet needs in cancer care. Recent highlights include positive early data for lead candidate ART27.13 and advancements in preclinical assets ART12.11 and ART26.12, targeting cancer treatment.
Artelo Biosciences (NASDAQ: ARTL), a clinical-stage biopharmaceutical company, will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 3:00 p.m. EST. During the virtual event, CEO Gregory D. Gorgas will discuss the company’s focus on therapeutics targeting lipid signaling pathways, particularly the endocannabinoid system. Artelo aims to address significant unmet medical needs across various conditions, including cancer and PTSD. Interested parties can access the presentation via a live webcast.
Artelo Biosciences (NASDAQ: ARTL) announced at the ICRS Symposium that Dr. Andrew Yates will present the ART27.13 Cancer Appetite Recovery Study poster on June 22. This study targets cancer anorexia, a condition affecting over 60% of late-stage cancer patients. Additionally, Prof. Saoirse O’Sullivan will present findings related to Artelo's ART12.11 CBD cocrystal on June 23, highlighting its potential in cancer care. Artelo aims to report initial results from the CAReS trial by Q4 2021, underscoring its focus on innovative therapies in oncology.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the LD Micro Invitational XI, scheduled for June 8-10, 2021. Gregory D. Gorgas, President and CEO, will host a virtual presentation on June 9 at 1:00 p.m. EST. Artelo focuses on developing therapeutics that impact the endocannabinoid system to address unmet medical needs in conditions like cancer and PTSD. For further details and registration, visit the LD Micro Invitational XI event page.
Kintara Therapeutics (Nasdaq: KTRA) announced the appointment of Tamara A. Seymour to its Board of Directors, replacing John Liatos, who remains as Senior VP of Business Development. Seymour, a seasoned finance executive with over 30 years in biotech, has successfully raised over $250 million in equity and debt financing. Under her leadership, Kintara progresses its cancer therapies, VAL-083 and REM-001, targeting glioblastoma and metastatic breast cancer, respectively. The Company aims to address significant unmet medical needs in oncology.
Artelo Biosciences has made significant strides in its clinical development, recently commencing patient enrollment in the Phase 1/2 CAReS study of ART27.13, aimed at treating cancer anorexia. The company reported positive pre-clinical results for its CBD cocrystal, ART12.11, showing enhanced efficacy in cancer models. Financially, Artelo holds approximately $11.2 million in cash and cash equivalents as of February 28, 2021, which provides ample runway for upcoming milestones. However, the net loss for the quarter was around $1.87 million, indicating ongoing financial challenges.
Artelo Biosciences (NASDAQ: ARTL) has announced the initiation of its Phase 1/2 Cancer Appetite Recovery Study (CAReS) for ART27.13, a therapeutic aimed at treating cancer-related anorexia affecting over 60% of late-stage cancer patients. The first patient has been dosed in Edinburgh, Scotland. The study aims to collect initial safety data by the end of 2021, assessing the drug's efficacy in increasing appetite and weight. ART27.13 targets a significant market devoid of approved therapies, with current global market valuation surpassing $2 billion.
Artelo Biosciences (NASDAQ: ARTL) has been accepted into the Alderley Park Oncology Development Program in the UK, which aims to support innovative oncology projects. This program, funded by Innovate UK and Cancer Research UK, could provide additional funding to Artelo's FABP5 inhibitor program, which has previously received nearly $8 million from the U.S. government. The program focuses on developing a pathway to validate FABP5 as a biomarker across multiple tumor types, suggesting broader applicability of ART26.12 in cancer therapy.
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that CEO Gregory Gorgas will present at the Q1 Virtual Investor Summit from March 23-25, 2021. The presentation is scheduled for March 23rd at 1:00 PM ET. This summit connects smallcap and microcap companies with qualified investors, featuring over 100 companies and 300 investors. Artelo focuses on developing therapeutics targeting lipid-signaling pathways, aiming to address significant health concerns such as cancer and pain. For more details, visit www.artelobio.com.